Therapie von schwangeren Patientinnen mit Abhängigkeit von

Opioidabhängige Schwangere und begleitende Suchtstoffe Übersicht
MMP
Therapie von schwangeren Patientinnen
mit Abhängigkeit von Opioiden und
begleitenden Suchtstoffen
Imke Hoell, Ursula Havemann-Reinecke, Ahmad Amanzada und Detlef Degner, Göttingen
Literatur
1.Adde-Michel C, Hennebert O, Laudenbach V, Marret S, et al. Effect of
acamprosate on neonatal excitotoxic cortical lesions in in utero alcoholexposed hamsters. Neurosci Lett 2005;374:109–12.
2.Arshad M, El-Kamary SS, Jhaveri R. Hepatitis C virus infection during
pregnancy and the newborn period – are they opportunities for treatment? J Viral Hepat 2011;18:229–36.
3.AWMF-Leitlinien für Sedativa/Benzodiazepine: http://www.awmf.org/
leitlinien/detail/ll/076–009.html.
4.AWMF-Leitlinien für Tabakbedingte Störungen. Leitlinie Tabakentwöhnung. [Artikel] // http://www.sucht.de/tl_files/pdf/11_05_03.pdf.
5.Batra A. [Tobacco dependence – evidence-based treatment strategies] Z Arztl Fortbild Qualitatssich 2002;96:281–6.
6.Berle JO, Solberg DK, Spigset O. [Treatment of bipolar disorder during pregnancy and in the postpartum period] Tidsskr Nor Laegeforen
2011;131:126–9.
7.Bleich S, Havemann-Reinecke U, Kornhuber J. Fagerström-Test für
Nikotin­abhängigkeit. Göttingen: Beltz Test GmbH, 2002.
8.Bohus M, editor. Borderline-Störung. Göttingen: Hogrefe Verlag für
Psychologie, 2002.
9.Bonnet U, Scherbaum N. Evidenzbasierte Behandlung der Cannabisabhängigkeit. Dt Ärzteblatt 2005;102:A3334–41.
10.Brzozka MM, Falkai P, Havemann-Reinecke U. Für Schizophrenie
braucht man Drei. Suchtmed 2009;11:98–103.
11. Brünen S, Vincent PD, Baumann P, Hiemke C, et al. Therapeutic drug
monitoring (TDM) for drugs used in the treatment of substance related
disorders. Literature review using a TDM appropriateness rating scale.
Ther Drug Monit 2011;33:561–72.
12.Budney AJ, Hughes JR, Moore BA, Vandrey R. Review of the validity­ and significance of cannabis withdrawal syndrome. Am J Psychiatry
2004;161:1967–77.
13.Burns L, Conroy E, Mattick RP. Infant mortality among women on a
methadone program during pregnancy. Drug Alcohol Rev 2010;29: 551–6.
14.Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension
of the newborn. N Engl J Med 2006;354:579–87.
15.Chasnoff IJ, Burns WJ, Schnoll SH, Burns KA. Cocaine use in pregnancy. N Engl J Med 1985;313:666–9.
16.Chung KC, Kowalski CP, Kim HM, Buchman SR. Maternal cigarette
smoking during pregnancy and the risk of having a child with cleft lip/
palate. Plast Reconstr Surg 2000;105:485–91.
17.Clark SM, Nakad R. Pharmacotherapeutic management of nicotine
dependence in pregnancy. Obstet Gynecol Clin North Am 2011;38: 297–311.
18.Cohen LS, Friedman JM, Jefferson JW, Johnson EM, et al. A reevaluation of risk of in utero exposure to lithium. JAMA 1994;271:146–50.
19.Cole JA, Modell JG, Haight BR, Cosmatos IS, et al. Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepi­
demiol Drug Saf 2007;16:474–84.
20.Coleman T, Chamberlain C, Cooper S, Leonardi-Bee J. Efficacy and
safety of nicotine replacement therapy for smoking cessation in pregnancy: systematic review and meta-analysis. Addiction 2011;06:52–61.
21.Coles CD, Platzman KA. Behavioral development in children prenatally
exposed to drugs and alcohol. Int J Addict 1993;28:1393–433.
22.De Sousa A. A one-year pragmatic trial of naltrexone vs. disulfiram in
the treatment of alcohol dependence. Alcohol Alcohol 2004;39:528–31.
23.Dempsey DA, Benowitz NL. Risks and benefits of nicotine to aid smoking cessation in pregnancy. Drug Saf 2001;24:277–322.
24.Deutsch-Österreichische Leitlinien zur HIV-Therapie bei Schwangeren und Neugeborenen. http://www.rki.de/DE/Content/InfAZ/H/ HIVAIDS/Therapie/Leitlinien/PDF__D__A__schwanger.html (Zugriff
am 24.10.2011).
25.Diav-Citrin O, Shechtman S, Ornoy S, et al. Safety of haloperidol and
penfluridol in pregnancy: a multicenter, prospective, controlled study. J Clin Psychiatry 2005;66:317–22.
26.Djulus J, Koren G, Einarson TR, et al. Exposure to mirtazapine during
pregnancy: a prospective, comparative study of birth outcomes. J Clin
Psychiatry 2006;67:1280–4.
27.Driessen M, Schulte S, Luedecke C, et al. Trauma and PTSD in patients
with alcohol, drug, or dual dependence: a multi-center study. Alcohol
Clin Exp Res 2008;32:481–8.
28.Drogen- und Suchtbericht 2011, http://www.drogenbeauftragte.de/
fileadmin/dateien-dba/Service/Publikationen/Drogen_und_Suchtbericht_2011_110517_Drogenbeauftragte.pdf (Zugriff am 24.10.2011).
29.Dusick AM, Covert RF, Schreiber MD, et al. Risk of intracranial hemorrhage and other adverse outcomes after cocaine exposure in a cohort of
323 very low birth weight infants. J Pediatr 1993;122:438–45.
30.Eiden RD, Schuetze P, Colder CR, Veira Y. Maternal cocaine use and
mother-toddler aggression. Neurotoxicol Teratol 2011;33:360–9.
31.Einarson A, Choi J, Einarson TR, Koren G. Incidence of major malformations in infants following antidepressant exposure in pregnancy:
results of a large prospective cohort study. Can J Psychiatry 2009;54: 242–6.
32.Empfehlung der ständigen Impfkommission des Robert-Koch-Institut
Stand April 2011 http://www.rki.de/cln_160/nn_199630/SharedDocs/
FAQ/Impfen/AllgFr__AllgemeineFragen/FAQ08.html (Zugriff am
24.10.2011).
33.Ericson A, Kallen B, Wiholm B. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999;55:503–8.
34.Ferger B, Havemann-Reinecke U, Kuschinsky K. Dopamin und
Suchterkrankungen. Med Monatsschr Pharm 1997;20:300–9.
Prof. Dr. Ursula Havemann-Reinecke, Dr. Imke Hoell, Dr. med. Detlef Degner,
Klinik für Psychiatrie und Psychotherapie, Universitätsmedizin Göttingen, VonSiebold-Straße 5, 37075 Göttingen, E-Mail: [email protected], [email protected]
Dr. med. Ahmad Amanzada, Klinik für Innere Medizin, Abteilung
Gastroenterologie und Endokrinologie, Universitätsmedizin Göttingen, RobertKoch-Straße 40, 37075 Göttingen
MMP 34. Jahrgang 11/2011
*1
MMP
Übersicht Opioidabhängige Schwangere und begleitende Suchtstoffe
35.Florescu A, Ferrence R, Einarson T, Selby P, et al. Methods for quantification of exposure to cigarette smoking and environmental tobacco smoke: focus on developmental toxicology. Ther Drug Monit
2009;31:14–30.
36.Fried PA, Watkinson B. 36- and 48-month neurobehavioral follow-up
of children prenatally exposed to marijuana, cigarettes, and alcohol. J Dev Behav Pediatr 1990;11:49–58.
37.Fried PA, Watkinson B, Gray R. Differential effects on cognitive functioning in 13- to 16-year-olds prenatally exposed to cigarettes and marihuana. Neurotoxicol Teratol 2003;25:427–36.
38.Galbally M, Roberts M, Buist A. Mood stabilizers in pregnancy: a systematic review. Aust N Z J Psychiatry 2010;44:967–77.
39.Gentile S. Drug treatment for mood disorders in pregnancy. Curr Opin
Psychiatry 2011;24:34–40.
40.Gentile S. Selective serotonin reuptake inhibitor exposure during
early pregnancy and the risk of birth defects. Acta Psychiatr Scand
2011;123:266–75.
41.Gerardin M, Victorri-Vigneau C, Louvigne C, Rivoal M, et al. Management of cannabis use during pregnancy: an assessment of healthcare
professionals’ practices. Pharmacoepidemiol Drug Saf 2011;20:464–73.
doi: 10.1002/pds.2095.
42.Glaeske B. Psychotrope und andere Arzneimittel mit Missbrauchs- und
Abhängigkeitspotenzial. In: Deutsche Hauptstelle für Suchtfragen e. V.
(Hrsg.). Jahrbuch Sucht 2009. Geesthacht: Neuland, 2009:93–4.
43.Gold LH. Treatment of depression during pregnancy. J Womens Health
Gend Based Med 1999;8:601–7.
44.Gouin K, Murphy K, Shah PS. Effects of cocaine use during pregnancy on low birthweight and preterm birth: systematic review and
metaanalyses. Am J Obstet Gynecol 2011;204:340–12.
45.Günthert A. Substanzkonsum in der Schwangerschaft. In: Mann K,
Havemann-Reinecke U, Gassmann R (Hrsg.). Jugendliche und Sucht­
mittelkonsum. Band 2, überarbeitete Auflage. Freiburg i. Br.: Lambertus, 2009:126–39.
46.Haustein KO. Cigarette smoking, nicotine and pregnancy. Int J Clin
Pharmacol Ther 1999;37:417–27.
47.Havemann-Reinecke U. Die Bedeutung zentraler dopaminerger Neurone für die Entwicklung von Abhängigkeit am Beispiel der Opioide.
Aachen: Shaker Verlag, 2002.
48.Hiemke C, Baumann P, Bergemann N, Conca A, et al. AGNP consensus
guidelines for therapeutic drug monitoring in psychiatry. Update 2011.
Pharmacopsychiatry 2011;44:195–235.
49.Hoffmann C, Rockstroh JK (editors). HIV 2010. Hamburg: Medizin
Fokus Verlag, 2010.
50.Holmes LB, Mittendorf R, Shen A, Smith CR, et al. Fetal effects
of anti­convulsant polytherapies: Different risks from different drug
combinations. Arch Neurol 2011;68:1275–81 (doi:10.1001/archneurol.2011.133).
51.Huizink AC, Mulder EJ. Maternal smoking, drinking or cannabis use
during pregnancy and neurobehavioral and cognitive functioning in
human offspring. Neurosci Biobehav Rev 2006;30:24–41.
52.Inder D, Rehan HS, Yadav M, Manak S, et al. IFN-alpha-2a (Interferon)
and ribavirin induced suicidal attempt in a patient of chronic HCV: A
rare case report. Indian J Pharmacol 2011;43:210–211.
53.Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med
2010;363:2320–31.
54.Jones KL, Smith DW. Recognition of the fetal alcohol syndrome in
early infancy. Lancet 1973;302:999–1001.
55.Kaaja E, Kaaja R, Hiilesmaa V. Major malformations in offspring of
women with epilepsy. Neurology 2003;60:575–9.
56.Kakko J, Heilig M, Sarman I. Buprenorphine and methadone treatment
of opiate dependence during pregnancy: comparison of fetal growth and
neonatal outcomes in two consecutive case series. Drug Alcohol Depend 2008;96:69–78.
57.Kandall SR, Doberczak TM, Jantunen M, Stein J. The methadone-maintained pregnancy. Clin Perinatol 1999;26:173–83.
58.Kaneko S, Battino D, Andermann E, et al. Congenital malformations
due to antiepileptic drugs. Epilepsy Res 1999;33:145–58.
59.Khare M, Taylor AH, Konje JC, Bell SC. Delta9-tetrahydrocannabinol
inhibits cytotrophoblast cell proliferation and modulates gene transcription. Mol Hum Reprod 2006;12:321–33.
*2
MMP 34. Jahrgang 11/2011
60.Klier CM, Mossaheb N, Saria A, Schloegelhofer M, et al. Pharmaco­
kinetics and elimination of quetiapine, venlafaxine, and trazodone during pregnancy and postpartum. J Clin Psychopharmacol 2007;27:720–2.
61.Lackmann GM, Salzberger U, Tollner U, Chen M, et al. Metabolites of a
tobacco-specific carcinogen in urine from newborns. J Natl Cancer Inst
1999;91:459–65.
62.Lacroix I, Berrebi A, Garipuy D, et al. Buprenorphine versus methadone
in pregnant opioid-dependent women: a prospective multicenter study.
Eur J Clin Pharmacol 2011;67:1053–9.
63.Leppee M, Culig J, Eric M, Sijanovic S. The effects of benzodiazepines
in pregnancy. Acta Neurol Belg 2010;110:163–7.
64.Little BB, Snell LM, Klein VR, Gilstrap LC, et al. Maternal and fetal
effects of heroin addiction during pregnancy. J Reprod Med 1990;35: 159–62.
65.Little BB, Wilson GN, Jackson G. Is there a cocaine syndrome? Dysmorphic and anthropometric assessment of infants exposed to cocaine.
Teratology 1996;54:145–9.
66.Lopez M, Coll O. Chronic viral infections and invasive procedures: risk
of vertical transmission and current recommendations. Fetal Diagn Ther
2010;28:1–8.
67.Malm H, Artama M, Gissler M, Ritvanen A. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol 2011;118:111–20.
68.McCance-Katz EF. Drug interactions associated with methadone, buprenorphine, cocaine, and HIV medications: Implications for pregnant
women. Life Sci 2011;88:953–8.
69.McElhatton PR. The effects of benzodiazepine use during pregnancy
and lactation. Reprod Toxicol 1994;8:461–75.
70.Naeye RL, Blanc W, Leblanc W, Khatamee MA. Fetal complications of
maternal heroin addiction: abnormal growth, infections, and episodes of
stress. J Pediatr 1973;83:1055–61.
71.Najavits LM. Seeking safety protocol for men and women. Psychiatr
Serv 2007;58:1376.
72.Norddeutscher Suchtforschungsverbund: www.nsfev.de
73.Nordeng H, Lindemann R, Perminov KV, Reikvam A. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake
inhibitors. Acta Paediatr 2001;90:288–91.
74.O’Reardon JP, Cristancho MA, von Andreae CV, Cristancho P, et al.
Acute and maintenance electroconvulsive therapy for treatment of severe major depression during the second and third trimesters of pregnancy with infant follow-up to 18 months: case report and review of the
literature. J ECT 2011;27:e23–6.
75.Oberlander TF, Warburton W, Misri S, Riggs W, et al. Major congenital
malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol 2008;83:68–76.
76.Oliveto A, Poling J, Mancino MJ, et al. Randomized, double blind,
placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drug Alcohol Depend
2011;113:184–91.
77.Ornoy A, Segal J, Bar-Hamburger R, Greenbaum C. Developmental
outcome of school-age children born to mothers with heroin dependency: importance of environmental factors. Dev Med Child Neurol
2001;43:668–75.
78.Ozkan H, Cetinkaya M, Koksal N, Yapici S. Severe fetal valproate
syndrome: combination of complex cardiac defect, multicystic dysplastic kidney, and trigonocephaly. J Matern Fetal Neonatal Med 2011;24:521–4.
79.Pariante CM, Seneviratne G, Howard L. Should we stop using tricyclic
antidepressants in pregnancy? Psychol Med 2011;41:15–7.
80.Parry BL, Curran ML, Stuenkel CA, et al. Can critically timed sleep
deprivation be useful in pregnancy and postpartum depressions? J Affect Disord 2000;60:201–12.
81.Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, et al. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations:
population based cohort study. BMJ 2009;339:b3569.
82.Peters H, Theorell CJ. Fetal and neonatal effects of maternal cocaine
use. J Obstet Gynecol Neonatal Nurs 1991;20:121–6.
83.Pinho AP, Nunes ML. Epidemiological profile and strategies for diagnosing SIDS in a developing country. J Pediatr (Rio J ) 2011;87:115–22.
Opioidabhängige Schwangere und begleitende Suchtstoffe Übersicht
84.Puente D, Cabezas C, Rodriguez-Blanco T, et al. The role of gender in
a smoking cessation intervention: a cluster randomized clinical trial.
BMC Public Health 2011;11:369.
85.Reis M, Källén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med
2010;40:1723–33.
86.Robert-Koch-Institut zur Inzidenz von Hepatitis A: http://www.rki.de/
cln_116/nn_468098/DE/Content/Infekt/EpidBull/Archiv/2008/44__0
8,templateId=raw,property=publicationFile.pdf/44_08.pdf (Zugriff am
24.10.2011).
87.Rohde A, Schaefer C. Psychopharmakotherapie in Schwangerschaft und
Stillzeit. Möglichkeiten und Grenzen. Stuttgart: Thieme, 2006:1.
88.Rupprecht R, Soyka M, Grohmann R, Rüther E, et al. Zur Problematik
der Kombination von Clozapin mit Benzodiazepinen. Der Nervenarzt 2004;75:857–60.
89.Saatcioglu O, Tomruk NB. The use of electroconvulsive therapy in
pregnancy: a review. Isr J Psychiatry Relat Sci 2011;48:6–11.
90.Saber-Tehrani AS, Bruce RD, Altice FL. Pharmacokinetic drug interactions and adverse consequeces between psychotropic medications and
pharmacotherapy for the treatment of opioid dependence. Am J Drug
Alcohol Abuse 2011;37:1–11.
91.Sampson PD, Streissguth AP, Bookstein FL, et al. Incidence of fetal alcohol syndrome and prevalence of alcohol-related neurodevelopmental
disorder. Teratology 1997;56:317–26.
92.Sarkola T, Eriksson CJ, Niemela O, Sillanaukee P, et al. Mean cell
volume­ and gamma-glutamyl transferase are superior to carbohydratedeficient transferrin and hemoglobin-acetaldehyde adducts in the follow-up of pregnant women with alcohol abuse. Acta Obstet Gynecol
Scand 2000;79:359–66.
93.Sasadeusz JJ, Dore G, Kronborg I, Barton D, et al. Clinical experience
with the treatment of hepatitis C infection in patients on opioid pharmacotherapy. Addiction 2011;106:977–84.
94.Sasco AJ, Vainio H. From in utero and childhood exposure to parental
smoking to childhood cancer: a possible link and the need for action.
Hum Exp Toxicol 1999;18:192–201.
95.Schäfer I, Langeland W, Hissbach J, et al. Childhood trauma and dissociation in patients with alcohol dependence, drug dependence, or both
– A multi-center study. Drug Alcohol Depend 2010;109:84–9.
96.Schäfer C, Spielmann H, Vetter L. Arzneimittelverordnung in Schwangerschaft und Stillzeit. 7. Auflage. München: Elsevier/Urban & Fischer,
2006.
MMP
97. Schmidt LG, Gastpar M, Falkai P, Gaebel W (editors). Evidenzbasierte Suchtmedizin. Behandlungsleitlinie Substanzbezogene Störungen.
Köln: Deutscher Ärzte-Verlag, 2006.
98. Schneider U, Altmann A, Baumann M, et al. Comorbid anxiety and
affective disorder in alcohol-dependent patients seeking treatment: the
first multicentre study in Germany. Alcohol Alcohol 2001;36:219–23.
99. Slone D, Siskind V, Heinonen OP, Monson RR, et al. Antenatal exposure to the phenothiazines in relation to congenital malformations,
perinatal mortality rate, birth weight, and intelligence quotient score.
Am J Obstet Gynecol 1977;128:486–8.
100. Spohr HL, Willms J, Steinhausen HC. Prenatal alcohol exposure and
long-term developmental consequences. Lancet 1993;341:907–10.
101. Stauber RE, Jauk B, Fickert P, Hausler M. Increased carbohydrate-deficient transferrin during pregnancy: relation to sex hormones. Alcohol
Alcohol 1996;31:389–92.
102. Sutton LR, Hinderliter SA. Diazepam abuse in pregnant women on
methadone maintenance. Implications for the neonate. Clin Pediatr
(Phila) 1990;29:108–11.
103. Thomas DB. Cleft palate, mortality and morbidity in infants of substance abusing mothers. J Paediatr Child Health 1995;31:457–60.
104. Udechuku A, Nguyen T, Hill R, Szego K. Antidepressants in pregnancy: a systematic review. Aust N Z J Psychiatry 2010;44:978–96.
105. Wedekind D, Jacobs S, Karg I, et al. Psychiatric comorbidity and additional abuse of drugs in maintenance treatment with l- and d,l-methadone. World J Biol Psychiatry 2008;9:1–10.
106. Wedekind D, Jacobs S, Poser W, Rüther E, et al. Comorbidity in heroin
and cocaine addiction. German Journal of Psychiatry 2009;12:1–8.
107. Wedekind D, Havemann-Reinecke U. Sucht, psychiatrische Komorbidität und das serotonerge System. Nervenheilkunde 2009;28:509–13.
108. Weinshenker D. Cocaine sobers up. Nat Med 2010;16:969–70.
109. Werler MM. Teratogen update: smoking and reproductive outcomes.
Teratology 1997;55:382–8.
110. Wong S, Ordean A, Kahan M. Substance use in pregnancy. J Obstet
Gynaecol Can 2011;33:367–84.
111. Mulder EJ, Ververs FF, de Heus R, Visser GH. Selective serotonin
reuptake inhibitors affect neurobehavioral development in the human
fetus. Neuropsychopharmacology 2011;36:1961–71. Epub 2011
Apr 27 (doi: 10.1038/npp.2011.67).
112. Koch L. SSRIs and congenital abnormalities. Nature Rev Endocrinol
2011;7:499.
MMP 34. Jahrgang 11/2011
*3